Biopsies of patients with NASH show decreased activity of FADS1 genes (encoding Liver Delta-6D and Delta-5D activities)* which is a key player in accumulating toxic lipids during NASH progression [88,89]. This evidence concerns the gene FADS1 and metabolic dysfunction-associated steatohepatitis.